LONDON, Jan. 27, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will report on 4 February, 2015 its first quarter financial results for the period ending 31 December, 2014. GW will also host a conference call the same day at 8:00 a.m. EST/1:00 p.m. GMT.
Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
Top Company Interviews
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. GW is also advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex®, which is in Phase 2/3 clinical development for the treatment of Dravet syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Lennox-Gastaut syndrome. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia.www.gwpharm.com.
GW Pharmaceuticals plc
(Today) +44 20 3727 1000
Justin Gover, Chief Executive Officer
(Thereafter) + 44 1980 557000
Stephen Schultz, VP Investor Relations (U.S.)
917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen (UK)
+ 44 20 3727 1000
Robert Stanislaro (U.S.)
212 850 5657
Trout Group, LLC (U.S. investor relations)
Todd James / Chad Rubin
646 378 2900
Source: GW Pharmaceuticals plc
News Provided by Acquire Media
This content was issued by GW Pharmaceuticals plc on the 2015-01-27 and was initially posted on www.gwpharm.com. It was distributed, unedited and unaltered, by noodls on 2015-01-27 07:02:27 UTC. The original issuer is solely responsible for the accuracy of the information contained therein.
Top Company Interviews
Register for a Free Account to gain greater access to
The Wall Street Transcript right now